Rituximab treatment for IgA vasculitis: A systematic review

Area of Science:

• Rheumatology
• Nephrology
• Immunology

Background:

• Immunoglobulin A vasculitis (IgAV) is a systemic small vessel vasculitis.
• Current treatments for severe IgAV involve glucocorticoids and immunosuppressants.
• Rituximab (RTX) has been explored for refractory IgAV cases.

Purpose of the Study:

• To review pediatric and adult IgAV patients treated with RTX.
• To assess RTX efficacy and safety in IgAV.
• To analyze disease characteristics and treatment outcomes.

Main Methods:

• Systematic literature review following PRISMA guidelines.
• Data extraction on patient characteristics, disease course, RTX efficacy, and safety.
• Analysis of 20 studies including 35 IgAV patients treated with RTX.

Main Results:

• 94.3% of patients showed clinical improvement with RTX.
• 74.3% achieved sustained remission; relapses were managed effectively with additional RTX doses.
• RTX significantly reduced the need for glucocorticoids and other immunosuppressants.
• Minor RTX-associated adverse effects occurred in 8.6% of patients, with no deaths.

Conclusions:

• RTX appears safe and effective for inducing remission in IgAV patients refractory to conventional therapy.
• RTX is beneficial for IgAV patients with contraindications to standard immunosuppressants.
• Further controlled clinical trials are needed to establish RTX's definitive role in IgAV management.